Moderna raises 2026 revenue outlook after third-quarter growth
Company / institutional announcement · Moderna / ACCESS Newswire
Source published: · Event / reporting date: 2026-11-06
Site published: 2026-11-06 · Updated: 2026-11-06
This source is linked automatically. Choose a question to get started.
What changed
Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and GAAP net income of $162 million, compared with a $200 million loss a year earlier. It raised expected full-year revenue growth to 15%–25% from up to 10%. The company attributed quarterly growth mainly to international COVID vaccine sales supported by government partnerships.
Why it may matter
Analysis: The results may inform assessments of mRNA manufacturing demand and platform funding capacity; revenue guidance remains forward-looking rather than guaranteed.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections